Research, Select, & Monitor Thursday, February 20, 2020 10:35:12 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
CTI BioPharma Corp.$1.24($.01)(.80%)

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  CTI BioPharma Corp. vs Drug Manufacturers/Other

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.

Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
 Totals Company Industry
  Sales: N/A $98,243.3 Mil
  Market Cap: $72.5 Mil $408,318.0 Mil
  Analysts Recommendation: N/A Buy

 Averages Company Industry
  Historic Revenue: N/A 13.9%
  Estimated Revenue: N/A 12.0%
  Historic Earnings: N/A 9.3%
  Estimated Earnings: N/A 81.9%
  Stock Price (1 Year): 31.6% 5.3%
  Cash per Share: N/A 154.3%
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: N/A 22.5
  Price-to-Sales: N/A N/A
  Price-to-Book: N/A 6.4
  Dividend Yield: N/A N/A
  Market Cap: $72.5 Mil $16,332.7 Mil
  Net Margin: N/A 58.6%
  Gross Margin: N/A 87.9%
  Return on Equity: N/A .3
  Return on Assets: N/A .1
  Balance Sheet
  Current Ratio: N/A 10.8
  Quick Ratio: N/A 10.5
  Cash Ratio: N/A 9.4
  Debt-to-Equity: N/A 2.7
  Interest Coverage: N/A 1.0
  Relative-Strength Index: 41.1 N/A

 Other companies in Drug Manufacturers/Other Price Market Cap
  Novo Nordisk A\/S  (NVO) $63.51 $151,883.5 Mil
  Allergan plc  (AGN) $198.74 $65,265.3 Mil
  Vertex Pharmaceuticals Inc.  (VRTX) $245.10 $63,716.6 Mil
  UBS AG  (UBS) $13.27 $48,128.1 Mil
  Alexion Pharmaceuticals, Inc.  (ALXN) $102.54 $22,850.7 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2020 All rights reserved.